| Literature DB >> 34587489 |
Gabrielle Lemire1, Yoko A Ito2, Aren E Marshall2, Nicolas Chrestian3, Valentina Stanley4, Lauren Brady5, Mark Tarnopolsky5, Cynthia J Curry6, Taila Hartley2, Wendy Mears2, Alexa Derksen7, Nadie Rioux8, Nataly Laflamme8, Harrol T Hutchison9, Lynn S Pais10, Maha S Zaki11, Tipu Sultan12, Adrie D Dane13, Joseph G Gleeson4, Frédéric M Vaz14, Kristin D Kernohan15, Geneviève Bernard16, Kym M Boycott17.
Abstract
ABHD16A (abhydrolase domain-containing protein 16A, phospholipase) encodes the major phosphatidylserine (PS) lipase in the brain. PS lipase synthesizes lysophosphatidylserine, an important signaling lipid that functions in the mammalian central nervous system. ABHD16A has not yet been associated with a human disease. In this report, we present a cohort of 11 affected individuals from six unrelated families with a complicated form of hereditary spastic paraplegia (HSP) who carry bi-allelic deleterious variants in ABHD16A. Affected individuals present with a similar phenotype consisting of global developmental delay/intellectual disability, progressive spasticity affecting the upper and lower limbs, and corpus callosum and white matter anomalies. Immunoblot analysis on extracts from fibroblasts from four affected individuals demonstrated little to no ABHD16A protein levels compared to controls. Our findings add ABHD16A to the growing list of lipid genes in which dysregulation can cause complicated forms of HSP and begin to describe the molecular etiology of this condition.Entities:
Keywords: ABHD16A; hereditary spastic paraplegia; intellectual disability; lysophosphatidylserine
Mesh:
Substances:
Year: 2021 PMID: 34587489 PMCID: PMC8546048 DOI: 10.1016/j.ajhg.2021.09.005
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025